July 26, 2016: Here are three stocks trading with relatively heavy volume among 20 equities making new 52-week lows in Tuesday’s session. NYSE advancers led decliners by about 3 to 2 and Nasdaq advancers led decliners by about the same margin.
Cardiome Pharma Corp. (NASDAQ: CRME) lost about 43% Tuesday to post a new 52-week low of $3.00 versus a high of $10.40 after closing Monday at $5.30. Volume totaled about 4.4 million shares, more than 100 times the daily average of just 43,000 shares. The company priced a secondary offering of 10 million shares at $3 a share this morning.
Noodles & Co. (NASDAQ: NDLS) dropped nearly 23% on Tuesday to post a new 52-week low of $8.01 after closing at $10.36 on Monday. The stock’s 52-week high is $15.88. Volume was about 10 times the daily average of around 114,000 shares. The fast casual restaurant chain announced management changes this morning and preliminary results that included a drop of 1% in same-store sales and lower revenues than analysts had forecast.
Tobira Therapeutics Inc. (NASDAQ: TBRA) dropped about 10% on Tuesday to post a new 52-week low of $4.03 against a 52-week high of $15.63. Volume of around 825,000 was more than 6 times the daily average of around 130,000. The stock closed at $4.50 on Monday night. The company reported Monday that a phase IIb trial of a liver disease treatment failed to meet its primary endpoint and the effects have not yet ended.
Get Ready To Retire (Sponsored)
Start by taking a quick retirement quiz from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes, or less.
Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.
Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future
Get started right here.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
